Quitting smoking before and after varenicline: A population study based on two representative samples of US smokers

Tobacco Control

Volumn 25, Issue 4, 2016, Pages 464-469

  Zhu, Shu Hong ^a   Cummins, Sharon E ^a   Gamst, Anthony C ^a   Wong, Shiushing ^a   Ikeda, Tyson ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINIC AGENT; VARENICLINE;

ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; QUESTIONNAIRE; RECURRENT DISEASE; SMOKING; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TOBACCO DEPENDENCE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BUPROPION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; RECURRENCE; SMOKERS; SMOKING CESSATION; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; UNITED STATES; VARENICLINE; YOUNG ADULT;

EID: 84940206704     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2015-052332     Document Type: Article

References (44)

1. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.
2. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64–71.
3. Klesges RC, Johnson KC, Somes G. Varenicline for smoking cessation: definite promise, but no panacea. JAMA 2006;296:94–5.
4. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47–55.
5. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561–8.
6. Hsueh K-C, Hsueh S-C, Chou M-Y, et al. Varenicline versus transdermal nicotine patch: a 3-year follow-up in a smoking cessation clinic in Taiwan. Psychopharmacology (Berl) 2014;231:2819–23.
7. Brose LS, West R, Stapleton JA. Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin Proc 2013;88:226–33.
8. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013;170:1460–7.
9. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
10. US Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). Rockville, MD: Department of Health and Human Services, 2009. (modified 29 Aug 2013). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm170090.htm (accessed 2015 Jun 15).
11. Kuehn BM. New reports examine psychiatric risks of varenicline for smoking cessation. JAMA 2012;307:129–30.
12. Syed BA, Chaudhari K. Smoking cessation drugs market. Nat Rev Drug Discov 2013;12:97–8.
13. King M. Smoking cessation medicine market led by Chantix and Champix. London: Vertical Edge Limited, 2013. http://www.companiesandmarkets.com/News/Healthcare-and-Medical/Smoking-cessation-medicine-market-led-by-Chantix-and-Champix/NI8217 (accessed 15 Jun 2015).
14. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013;159:390–400.
15. Koegelenberg CFN, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014;312:155–61.
16. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014;311:155–63.
17. Kasza KA, Cummings KM, Carpenter MJ, et al. Use of stop-smoking medications in the United States before and after the introduction of varenicline. Addiction 2015;110:346–55.
18. Shin DW, Suh B, Chun S, et al. The prevalence of and factors associated with the use of smoking cessation medication in Korea: Trend between 2005–2011. PLoS ONE 2013;8:e74904.
19. Molero Y, Lichtenstein P, Zetterqvist J, et al. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ 2015;350:h2388.
20. Langley TE, Huang Y, McNeill A, et al. Prescribing of smoking cessation medication in England since the introduction of varenicline. Addiction 2011;106: 1319–24.
21. Fix BV, Hyland A, Rivard C, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health 2011;8:222–33.
22. Kotz D, Fidler JA, West R. Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications? Nicotine Tob Res 2011;13:793–9.
23. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008;35:158–76.
24. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health 2005;26:583–99.
25. Fiore MC, Keller PA, Curry SJ. Health system changes to facilitate the delivery of tobacco-dependence treatment. Am J Prev Med 2007;33:S349–56.
26. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains—in our lifetime. Am J Prev Med 2007;33:S340–8.
27. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013;5:CD000165.
28. U.S. Census Bureau. Current Population Survey: design and methodology. Washington, U.S: Department of Labor, Bureau of Labor Statistics; U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau, 2002. Technical paper 63R. 228. http://www.census.gov/prod/2002pubs/tp63rv.pdf (accessed 15 Jun 2015).
29. U.S. Census Bureau. Current Population Survey: design and methodology. Washington, U.S: Department of Labor, Bureau of Labor Statistics; U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau, 2006: 175. Technical paper 66. http://www.census.gov/prod/2006pubs/tp-66.pdf (accessed 15 Jun 2015).
30. Gilpin EA, Pierce JP, Farkas AJ. Duration of smoking abstinence and success in quitting. J Natl Cancer Inst 1997;89:572–6.
31. Zhu S-H, Lee M, Zhuang Y-L, et al. Interventions to increase smoking cessation at the population level: how much progress has been made in the last two decades? Tob Control 2012;21:110–18.
32. SAS Institute Inc. SAS® 9.4 language reference: concepts. 4th edn. Cary, NC: SAS Institute, 2014:724. http://support.sas.com/documentation/cdl/en/lrcon/67885/PDF/default/lrcon.pdf (accessed 15 Jun 2015).
33. U.S. Census Bureau. Current Population Survey, February, June, and November 2003: Tobacco Use Supplement file. Washington, U.S: Census Bureau, 2006: 348. Technical documentation: CPS-03. http://www.census.gov/prod/techdoc/cps/cpsfebjunnov03.pdf (accessed 15 Jun 2015).
34. U.S. Census Bureau. Current Population Survey, January 2011: tobacco use file. Washington, U.S: Census Bureau, 2011: 475. Technical documentation: CPS-11. http://www.census.gov/prod/techdoc/cps/cpsjan11.pdf (accessed 15 Jun 2015).
35. Research Triangle Institute. SUDAAN language manual, volumes 1 and 2, release 11. Research Triangle Park, NC: Research Triangle Institute, 2012:1396.
36. Agency for Healthcare Research and Quality. Guide to clinical preventive services, 2007: Recommendations of the U.S. Preventive Services Task Force. Report No.: 07-05100. Rockville, MD: Agency for Healthcare Research and Quality (US), 2007. https://www.ncbi.nlm.nih.gov/books/NBK16363/
37. Centers for Disease Control and Prevention (CDC). State Medicaid coverage for tobacco-dependence treatments—United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1340–3.
38. Hyland A, Rezaishiraz H, Giovino G, et al. Over-the-counter availability of nicotine replacement therapy and smoking cessation. Nicotine Tob Res 2005;7:547–55.
39. Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems. CNS Drugs 2013;27:1007–19.
40. Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010;7:e1000216.
41. Polosa R, Morjaria JB, Caponnetto P, et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern Emerg Med 2014;9:537–46.
42. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013;382:1629–37.
43. Bhatnagar A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation 2014;130:1418–36.
44. West R, DiMarino ME, Gitchell J, et al. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control 2005;14:166–71.